Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Biospyder Technologies Inc
Profile last edited on: 9/26/22      CAGE: 6THH7      UEI: KLCPP1J49GC5

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2012
First Award
2013
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2736 Loker Avenue West Suite B
Carlsbad, CA 92010
   (760) 476-1800
   N/A
   www.biospydertechnologies.com
Location: Single
Congr. District: 49
County: San Diego

Public Profile

BioSpyder is a molecular profiling company engaged in the development and commercialization of TempO-Seq technology, a novel expression profiling assay platform for measuring DNA, RNA and Proteins. TempO-seq is a robust, inexpensive and versatile assay platform well suited for rapid modification for many molecular profiling applications involving DNA, RNA and Proteins. The firm offer whole transcriptome products for human, Rat and mouse but can quickly develop fixed or custom panels for any signature, species or sample type.

Extent of SBIR involvement

User Avatar
Phase I Awards
17
Phase II Awards
6
Conversion Rate
35.29%
Phase I Dollars
$4,417,321
Phase II Dollars
$8,479,278
Total Awarded
$12,896,599

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $1,858,212
Project Title: Whole Blood Filter Paper Assay for Alzheimers Disease
2023 2 NIH $1,643,551
Project Title: TempO-LINC high throughput, high sensitivity single cell gene expression profiling assay
2021 1 NIH $252,121
Project Title: TempO-Seq assay and cell panel for assessing impact of genetic diversity on compound bioactivity and toxicity risk
2021 2 NIH $1,413,116
Project Title: TempO-Seq Profiling of RNA Epitranscriptomic Modifications
2020 1 NIH $224,980
Project Title: Functional Read-Out Enabling High Compound Throughput Toxicokinetic Assays

Key People / Management

  Joel Mccomb -- Founder and CE

  Milos Babic

  Susanne L Cassidy

  Bruce E Seligmann -- Founder, Board Member and Chief Science Officer

  Bruce E Seligmann -- Chief Scientific Officer and Co-Founder

  Christine Yeakley -- Web Developer (volunteer)

  Joanne M Yeakley -- VP, R&D and Co-FounderVP, R&D and Co-Founder

Company News

There are no news available.